Spinal Cord Stimulation Combined With Physical Therapy in Post-Stroke Upper-Limb Motor Hemiparesis
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Number and Severity of Adverse Events
研究概览
简要总结
This study plans to use systems that have been developed by Medtronic to investigate the use of cervical spinal cord stimulation to treat adults with upper limb hemiparesis resulting from a stroke. The spinal cord stimulation (SCS) will be combined with physical training to improve arm and hand motor control. The study is divided into three phases. In the first phase, after baseline assessments, participants will undergo a Physical Training Protocol (PTP) for 6 weeks including 3 sessions of 90 mins/session per week. After receiving the Medtronic implantable system, in Phase 2, they will then repeat the same PTP program in combination with spinal cord stimulation during the entirety of each of the rehabilitation sessions. Finally, in Phase 3, participants will go home, will not be able to use the stimulation at home but will participate in monthly assessments in the laboratory in which the functionality of the Medtronic system and their motor performances will be assessed for up to 6 months.
详细描述
The main goal for this study is to evaluate safety of the Medtronic system in the stroke population. The second goal of this study is to assess and document the effects of SCS on motor control. More specifically, whether the combination of SCS and physical exercise (PTP+SCS) will improve motor control and reduce impairments, with the goal of optimizing inclusion criteria and outcome measures for future efficacy studies. To achieve this goal, we designed a study based on the rationale that the ramp up PTP phase 1 will bring people to a plateau motor impairment, in consequence any improvement upon this plateaued level should be due to the intervention.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Device Feasibility
- 盲法
- None
入排标准
- 年龄范围
- 22 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Experienced an ischemic or hemorrhagic stroke that resulted in arm and hand hemiparesis more than 6 months prior to the time of enrollment (Prior strokes that did not cause upper extremity motor deficits are not exclusionary.)
- •Age 22 to 70 years old
- •Upper extremity motor score higher than 20 and lower than or equal to 45 on the Fugl-Meyer Assessment (FMA) scale
- •FMA upper extremity sensory score higher than 6 points (out of 12 points)
- •The ability to communicate, understand, give appropriate consent and follow two-step commands
排除标准
- •Presence of any serious disease or disorder (ex. Neurological conditions other than stroke, cancer, severe cardiac or respiratory disease, renal failure, etc.) that could affect their ability to participate in this study
- •Considered to be at high-risk of recurrent stroke as evident from their medical history or upon judgment of the study physician
- •Presence of post-stroke central pain, other forms of pain or other constraints such as joint contractures in the paretic arm that are serious enough to prevent or affect the correct execution of the physical training protocol as judged by the study therapist
- •A score on the Short Blessed Test assessment scale lower than 9
- •Female participants of child-bearing age who are pregnant or breastfeeding during the study
- •Participants that cannot suspend their antiplatelets and/or anticoagulant therapy for two weeks around the time of surgery
- •Existence of any implanted medical device that is not MRI safe and/or any active medical devices even if it is MRI safe
- •Implanted spinal fusion and stabilization devices such as plates and rods between the C2 and T3 spinal vertebra
- •Obstructed or restricted epidural spinal canal to the point of hindering or increasing the risk of implant of the spinal leads as judged by the study surgeon upon screening imaging
- •Severe claustrophobia that prevents execution of the required MRI imaging sessions
- •Taking anti-spasticity or anti-epileptic medications
- •T-score higher than 63 on the 18-question Brief Symptoms Inventory (BSI-18) who have undergone discussions with and been deemed unsuitable by the Principal Investigator and a study physician
- •Potential participants who may be excluded on initial screening may discuss possible medication changes with their physician.
研究组 & 干预措施
Physical Therapy Alone, then Combined with Spinal Cord Stimulation
Two percutaneous leads will be implanted unilaterally on the affected side in the epidural space of the C3-T1 vertebrae (Medtronic Vectris™ SureScan™ 1x8). The leads will be connected to an external stimulator (Medtronic Inceptiv™ spinal cord neurostimulation system) during research activities.
干预措施: Spinal Cord Stimulator (Medtronic Inceptiv™ System) (Device)
Physical Therapy Alone, then Combined with Spinal Cord Stimulation
Two percutaneous leads will be implanted unilaterally on the affected side in the epidural space of the C3-T1 vertebrae (Medtronic Vectris™ SureScan™ 1x8). The leads will be connected to an external stimulator (Medtronic Inceptiv™ spinal cord neurostimulation system) during research activities.
干预措施: Physical Therapy (Other)
结局指标
主要结局
Number and Severity of Adverse Events
时间窗: From enrollment to the end of treatment at 49 weeks
Success Criteria: no serious adverse events related to the stimulation or intolerable. adverse events reported
次要结局
- Motor Impairment - Absolute Change(Baseline to the end of Phase 2 (19 weeks))
- Spasticity - Phase 2(Phase 2 (7 weeks))
- Spasticity - Absolute Change(Baseline to the end of Phase 2 (19 weeks))
- Strength - Phase 2(Phase 2 (7 weeks))
- Motor Control - Phase 2 and 3(Phase 2 through Phase 3 (31 weeks))
- Motor Impairment - Absolute Change(Baseline to the end of Phase 2 (19 weeks))
- Spasticity - Phase 2(Phase 2 (7 weeks))
- Spasticity - Absolute Change(Baseline to the end of Phase 2 (19 weeks))
- Strength - Phase 2(Phase 2 (7 weeks))
- Motor Control - Phase 2 and 3(Phase 2 through Phase 3 (31 weeks))
- Motor Impairment - Post Implant to end of Phase 2(Post implant to the end of Phase 2 (11 weeks))
研究者
Marco Capogrosso
Assistant Professor
University of Pittsburgh